All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is an independent medical education platform, supported by educational grants. We would like to express our gratitude to the following companies for their support: UCB, founding supporter. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View psoriasis and psoriatic arthritis content recommended for you
3-year BE RADIANT phase IIIb OLE results: Bimekizumab in PsO
Do you know... Which of the following statements is true regarding PASI100 rates at 3 years in patients with PsO who received bimekizumab in the BE RADIANT OLE?
Results from the open-label extension (OLE) of the phase IIIb BE RADIANT trial, which assessed the efficacy and safety of continuous bimekizumab, demonstrate the efficacy and safety of long-term dual inhibition of IL-17A/IL-17F with bimekizumab, compared with IL-17A inhibition alone with secukinumab.1
At 3 years, there was no difference in complete skin clearance (PASI100) or other outcomes between patients who received continuous treatment with bimekizumab and those who switched from secukinumab.1 No new safety signals were observed with continued exposure to bimekizumab.1
This educational resource is independently supported by UCB. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
On average, how many patients with plaque psoriasis do you see per month?
